Resumen

Introduction: Salmonella enteric serovar Typhi is the causative agent of typhoid fever with over 22 million cases and over 200,000 deaths reported annually. A vaccine is much needed for use in young children and the Novartis Vaccines Institute for Global Health (NVGH) is developing a conjugate vaccine which targets S. Typhi Vi capsular polysaccharide. Methodology: Here we describe a method suitable for industrial scale production of the Vi antigen based on expression by a Citrobacter line. We optimized the production of Vi by selecting a suitable Citrobacter strain (Citrobacter 328) that yields high and stable expression of Vi in chemically defined medium under industrial-scale fermentation conditions. Results: Vi-CRM₁₉₇ made using Vi from Citrobacter 328 elicited high anti-Vi antibody levels in mice and rabbits. Conclusions: Citrobacter

Palabras clave: S. Typhi Vi Citrobacter conjugate vaccine Vi-CRM197.

2013-01-18   |   427 visitas   |   Evalua este artículo 0 valoraciones

Vol. 6 Núm.11. Noviembre 2012 Pags. 763-773 J Infect Developing Countries 2012; 6(11)